Purdue Signs Two Deals To Diversify Portfolio

Purdue Pharma has made headway this month on its 2016-initiated plans to diversify the company's R&D portfolio away from the pain therapy space, having actioned two collaborative deals with Exicure and AnaBios.

businessman and businesswoman are exchanging document or contract
• Source: Shutterstock

Purdue Pharma LP and Exicure Inc. have entered a strategic research collaboration, option and license agreement to discover and develop a treatment for psoriasis.

The deal also covers R&D for other diseases amenable to a gene regulation approach utilizing Exicure's spherical nucleic acid (SNA)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.